MTOR and hepatocellular carcinoma: A strategy accounting for the need to inhibit or degrade both AR-FL and AR-SVs as well as carefully exploring the resulting impacts upon mTOR in both AR-SV positive and AR-SV negative disease may prove beneficial in treating HCC.